STRO — Sutro Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $83.75m
- -$83.85m
- $62.04m
- 25
- 37
- 57
- 33
Annual cashflow statement for Sutro Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -32.1 | -106 | -119 | -107 | -227 |
| Depreciation | |||||
| Non-Cash Items | -28.5 | 36.6 | 12.7 | 22.7 | 19.8 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -11.5 | -17.6 | 104 | -34.4 | 8.9 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -67.8 | -81.7 | 3.55 | -112 | -192 |
| Capital Expenditures | -7.13 | -15.3 | -7.86 | -4.32 | -3.1 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 7.73 | -82 | -27.2 | 0.391 | 222 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.604 | -97.3 | -35 | -3.92 | 219 |
| Financing Cash Flow Items | -0.314 | 0.778 | -0.463 | 138 | -0.509 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 269 | 3.26 | 48.3 | 138 | 94.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 202 | -176 | 16.8 | 22 | 121 |